How to improve adherence the captors of phosphorus on hemodialysis: experience in real life with sucroferric oxyhydroxide

Introduction: The lack of adherence to phosphate -binders (PB) is the most important factor in not achieving the objectives of serum phosphorus (sP). Studies in the real-world population are needed to understand the influence of PBs on adherence and how to modify it. Methods: Prospective study condu...

ver descrição completa

Detalhes bibliográficos
Autores: Arenas, María Dolores (Arenas Jiménez), Navarro González, Juan Francisco
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/46126
Acesso em linha:http://hdl.handle.net/10230/46126
http://dx.doi.org/10.1016/j.nefro.2020.04.011
Access Level:acceso abierto
Palavra-chave:Adherence
Adherencia
Aglutinantes de fosfato
Patient preferences
Patient–physician relationship
Phosphate binders
Preferencias del paciente
Relación médico-paciente
id ES_d8ffe8c1dd70fb55a75c6c46cd8a61c9
oai_identifier_str oai:recercat.cat:10230/46126
network_acronym_str ES
network_name_str España
repository_id_str
spelling How to improve adherence the captors of phosphorus on hemodialysis: experience in real life with sucroferric oxyhydroxideArenas, María Dolores (Arenas Jiménez)Navarro González, Juan FranciscoAdherenceAdherenciaAglutinantes de fosfatoPatient preferencesPatient–physician relationshipPhosphate bindersPreferencias del pacienteRelación médico-pacienteIntroduction: The lack of adherence to phosphate -binders (PB) is the most important factor in not achieving the objectives of serum phosphorus (sP). Studies in the real-world population are needed to understand the influence of PBs on adherence and how to modify it. Methods: Prospective study conducted during 3 months in usual clinical practice. Out of 105 hemodialysis patients, 57 were switched to SFOH and 48 maintained their baseline treatment (control group). sP levels and the percentage of patients with sP levels <5mg/dl were compared. Adherence before and after introduction of SFOH, number of pills of PB, preferences in the administration mode and side effects were analyzed. Results: The percentage of patients with controlled sP (<5mg/dl) increased significantly in the SFOH users' group (62.1-92.9%, p<0.001), but not in the control group (83-83.3%, p=NS). The average of daily tablets decreased significantly in the SFOH group (7.2-2.3 comp, p<0.001), but not in the control group (5.6-5.6, p=NS) and 100% of the patients used only one PB in SFOH group. The use of SFOH increased the adherence according to the SMAQ questionnaire (57.8-84.3%; OR 13.1, p<0.001). The possibility to choose the preferred mode of administration (split-swallowing 89% compared to chewing 11%), improved the acceptance (44.7-78%). 14% of the patients experienced side effects and in 5.2% SFOH was discontinued for this reason. Conclusions: SFOH controlled serum sP in 93% of patients, 100% in monotherapy, and with fewer tablets. The exploration and adaptation of preferences in the mode of administration influenced the acceptance of the drug by the patient and, probably, the future adherence.Elsevier202120212020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/46126http://dx.doi.org/10.1016/j.nefro.2020.04.011reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)Inglés0211-6995 / © 2020 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. Esta obra está licenciada por una Licencia Creative Commons Attribution 4.0 International License. https://creativecommons.org/licenses/by-nc-nd/4.0/http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:10230/461262026-05-29T05:05:01Z
dc.title.none.fl_str_mv How to improve adherence the captors of phosphorus on hemodialysis: experience in real life with sucroferric oxyhydroxide
title How to improve adherence the captors of phosphorus on hemodialysis: experience in real life with sucroferric oxyhydroxide
spellingShingle How to improve adherence the captors of phosphorus on hemodialysis: experience in real life with sucroferric oxyhydroxide
Arenas, María Dolores (Arenas Jiménez)
Adherence
Adherencia
Aglutinantes de fosfato
Patient preferences
Patient–physician relationship
Phosphate binders
Preferencias del paciente
Relación médico-paciente
title_short How to improve adherence the captors of phosphorus on hemodialysis: experience in real life with sucroferric oxyhydroxide
title_full How to improve adherence the captors of phosphorus on hemodialysis: experience in real life with sucroferric oxyhydroxide
title_fullStr How to improve adherence the captors of phosphorus on hemodialysis: experience in real life with sucroferric oxyhydroxide
title_full_unstemmed How to improve adherence the captors of phosphorus on hemodialysis: experience in real life with sucroferric oxyhydroxide
title_sort How to improve adherence the captors of phosphorus on hemodialysis: experience in real life with sucroferric oxyhydroxide
dc.creator.none.fl_str_mv Arenas, María Dolores (Arenas Jiménez)
Navarro González, Juan Francisco
author Arenas, María Dolores (Arenas Jiménez)
author_facet Arenas, María Dolores (Arenas Jiménez)
Navarro González, Juan Francisco
author_role author
author2 Navarro González, Juan Francisco
author2_role author
dc.subject.none.fl_str_mv Adherence
Adherencia
Aglutinantes de fosfato
Patient preferences
Patient–physician relationship
Phosphate binders
Preferencias del paciente
Relación médico-paciente
topic Adherence
Adherencia
Aglutinantes de fosfato
Patient preferences
Patient–physician relationship
Phosphate binders
Preferencias del paciente
Relación médico-paciente
description Introduction: The lack of adherence to phosphate -binders (PB) is the most important factor in not achieving the objectives of serum phosphorus (sP). Studies in the real-world population are needed to understand the influence of PBs on adherence and how to modify it. Methods: Prospective study conducted during 3 months in usual clinical practice. Out of 105 hemodialysis patients, 57 were switched to SFOH and 48 maintained their baseline treatment (control group). sP levels and the percentage of patients with sP levels <5mg/dl were compared. Adherence before and after introduction of SFOH, number of pills of PB, preferences in the administration mode and side effects were analyzed. Results: The percentage of patients with controlled sP (<5mg/dl) increased significantly in the SFOH users' group (62.1-92.9%, p<0.001), but not in the control group (83-83.3%, p=NS). The average of daily tablets decreased significantly in the SFOH group (7.2-2.3 comp, p<0.001), but not in the control group (5.6-5.6, p=NS) and 100% of the patients used only one PB in SFOH group. The use of SFOH increased the adherence according to the SMAQ questionnaire (57.8-84.3%; OR 13.1, p<0.001). The possibility to choose the preferred mode of administration (split-swallowing 89% compared to chewing 11%), improved the acceptance (44.7-78%). 14% of the patients experienced side effects and in 5.2% SFOH was discontinued for this reason. Conclusions: SFOH controlled serum sP in 93% of patients, 100% in monotherapy, and with fewer tablets. The exploration and adaptation of preferences in the mode of administration influenced the acceptance of the drug by the patient and, probably, the future adherence.
publishDate 2020
dc.date.none.fl_str_mv 2020
2021
2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/46126
http://dx.doi.org/10.1016/j.nefro.2020.04.011
url http://hdl.handle.net/10230/46126
http://dx.doi.org/10.1016/j.nefro.2020.04.011
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869421274129760256
score 15,198674

Registos relacionados